Hikma releases mercaptopurine oral suspension

Hikma is introducing mercaptopurine oral suspension, in a 20mg/ml dose, which is the first generic of this product.

Hikma was the first approved applicant with a Competitive Generic Therapy designation from the Food and Drug Administration. Therefore, Hikma is eligible for 180 days of CGT exclusivity.

Mercaptopurine oral suspension is indicated for the treatment of patients with acute lymphoblastic leukemia as part of a combination chemotherapy maintenance regimen. 

[Read more: Hikma intros Kloxxado]

Mercaptopurine oral suspension, 20mg/ml had a market value of approximately $14 million in the 12 months ending December 2024, per IQVIA.

Hafrun Fridriksdottir, president of Hikma’s generics business, said, “We are proud to introduce the first generic of Mercaptopurine Oral Suspension to patients in the U.S. Developed by our internal R&D team, this launch demonstrates our commitment to improving patient access to high-quality medicines."

[Read more: Hikma launches foscarnet sodium injection]